Ascensus Specialties is a leading U.S.-based provider of specialty materials used in life sciences and other advanced technology applications. The Company supplies a diversified portfolio of high-quality reagents, cGMP products, lab research chemicals and other specialty materials to customers in the pharmaceutical, microelectronics, and other specialty end markets. Ascensus is the only Western-based provider of its core chemistries and has superior technical capabilities, including 20+ PhDs, to support customers on complex application development. The Company is headquartered in Elma, WA and also has facilities outside Pittsburgh, PA and Boston, MA, including a rapidly growing cGMP manufacturing site for the life sciences industry.
New Mountain invested in Ascensus as a result of the firm’s multi-year, proactive “deep dive” effort in the specialty materials and life sciences sectors, which has led to our previous investments in Avantor, Gelest, Aceto, and ILC Dover. As part of the transaction, Ascensus’s management and previous investor, Wind Point Partners, reinvested alongside New Mountain.